24/7 Market News Snapshot 23 June, 2025 – Skye Bioscience, Inc. Common Stock (NASDAQ:SKYE)

June 23, 2025

DENVER, Colo., 23 June, 2025 (www.247marketnews.com) – (Nasdaq:SKYE) are discussed in this article.
Skye Bioscience, Inc. (Nasdaq:SKYE) has captured significant investor attention as it trades at $2.514 in pre-market sessions, reflecting a robust 16.39% rise from the previous close of $2.160. This surge is accompanied by a trading volume of 1.40 million shares, signaling heightened market enthusiasm and investor confidence. The increase in share price is further supported by positive technical indicators that may confirm a sustained bullish trend. Investors are encouraged to monitor these trends closely as market dynamics evolve.

In tandem, Skye Bioscience has unveiled an informative video series titled “Anatomy of Progress,” which focuses on the development of its innovative anti-obesity drug, nimacimab. This series aims to highlight advancements in addressing obesity, a pressing public health concern, and reflects the company’s dedication to improving therapeutic options in this critical field. During the recent 85th Scientific Sessions of the American Diabetes Association, Skye’s leadership discussed nimacimab’s unique targeting of peripheral CB1 receptors, setting it apart from conventional anti-obesity therapies that often carry neuropsychiatric side effects.

CEO Punit Dhillon articulated the importance of nimacimab in combating what he describes as a resistant biological state. He emphasized its potential to provide a safer alternative for weight management, addressing the urgent need for innovative treatments in the realm of metabolic health. The “Anatomy of Progress” series comprises four chapters that delve into nimacimab’s advantages, its clinical development, and market opportunities, as well as compelling pre-clinical findings.

As Skye Bioscience continues to position itself as a leader in the biotechnology sector, its commitment to advancing solutions in metabolic health is more evident than ever. The company’s initiatives invite engagement from stakeholders and the broader public, promoting a deeper understanding of its pioneering efforts in therapeutic innovation.

Related news for (SKYE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.